## A Collaborative Antimicrobial Stewardship Initiative Requiring Mandatory Approval of Peripherally Inserted **Central Venous Catheters**



# Background

- Peripherally inserted central venous catheters (PICCs) are often used in patients that require prolonged intravenous (IV) antimicrobial administration
- Despite the benefits of PICCs, they are associated with complications, such as catheter occlusion or rupture, venous thrombosis and central line-associated bloodstream infections (CLABSIs)<sup>1</sup>
- At Augusta University Health (AUH), it was observed that ~50% of PICCs that were placed for administration of IV antimicrobials were unnecessary
- A novel initiative was implemented, which required antimicrobial stewardship/infectious diseases (ID) approval for PICC insertion if the indication was for IV antimicrobial administration only
- The objectives of this study were to describe the interventions, clinical outcomes and financial outcomes associated with requiring antimicrobial stewardship/infectious diseases approval for PICC insertion for IV antimicrobial administration

# Methods

- A retrospective observational study was conducted at AUH, a 520-bed tertiary care institution
- As part of the Antimicrobial Stewardship Program, the Medical Executive Committee approved a mandate that included requiring approval of PICC line insertions by the Antimicrobial Stewardship Program
- This study was approved by the AUH Institutional Review Board
- All adult patients with a PICC line insertion order for IV antimicrobial administration, between December 2017 and May 2019, were included
- The variables collected were: infection indications for PICC insertion, infectious diseases consultation, reason for PICC denial and 30-day PICC-related complications



## Sonal Patel, PharmD<sup>1</sup>, Aaron Chase, PharmD<sup>2</sup>, Eti Ebong, PharmD<sup>2</sup>, Jose Vazquez, MD<sup>3</sup>

<sup>1</sup> Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA <sup>2</sup> Department of Pharmacy, Augusta University Health, Augusta, GA <sup>3</sup>Department of Medicine, Augusta University Health/Medical College of Georgia, Augusta, GA

PICC is warranted



	<b>Cost Savings</b>	
	# Avoided	Cost pe Occurre
PICC insertion	109	\$2,580
CLABSI <sup>2</sup>	2	\$63,00
Deep vein thrombosis <sup>2,3</sup>	8	\$5,040
	Tot	al cost sav

- duration of antimicrobial being less than 28 days
- Treatment of bone and joint infections were the most common infection
- Of the 104 patients that received a PICC, 10 patients experienced a PICC-associated complication
- Avoiding 109 PICC insertions resulted in a cost savings of \$447,540
- This study shows the benefit of implementing an antimicrobial stewardship/infectious diseases approval process of PICC line insertions in hospitalized patients or in patients being considered for outpatient parenteral antimicrobial therapy
- This method not only decreased the adverse events associated with PICC lines, but it also helped save a significant amount of money

- 2014; 69:1695-1700.
- *Outcomes Res.* 2015; 7:451-462.

The authors of this presentation have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation.



Street - Rhoads Building (Ground Floor) niladelphia, PA 19104 hone: 267-226-2398

### Intervention

Reasons for PICC Denial n (%)		
Midline catheter preferred	56 (50%)	
Switched to oral antibiotics	40 (36%)	
Further work-up required	3 (3%)	
No antibiotics warranted	8 (7%)	
Other	4 (4%)	

### Outcomes



## **Discharge Disposition**

## References

Infection at PICC insertion site

Conant MM, Erdman SM, Osterholzer. Mandatory infectious diseases approval of outpatient parenteral antimicrobial therapy (OPAT): clinical and economic outcomes of averted cases. J Antimicrob Chemother.

1 (1%)

2. Krein, SL, Saint S, Trautner BW, et al. Patient-reported complications related to peripherally inserted central catheters: a multicenter prospective cohort study. BMJ Qual Saf. 2019. 28(7):574-581. 3. Fernandez MM, Hogue S, Preblick R, et al. Review of the cost of venous thromboembolism. *Clinicoecon* 

## Disclosures